REDUSE trial enrolls Patient 600!

(December 8) The REDUSE trial recently recruited its 600th patient, constituting another significant achievement in its pursuit of improving treatment for patients with septic shock.

With this milestone, this international, randomized study continues to enjoy steady enrollment of trial participants toward its recruitment target, placing the trial recruitment slightly ahead of the planned schedule.

The REDUSE team is grateful to all participating patients, healthcare professionals, and research teams, without whom our goal of advancing treatments for septic shock would not be possible. We look forward to sharing future achievements and findings from this important trial on critical care soon.